BIOGEN INC. Payments to Noncontrolling Interests
BIOGEN INC. (BIIB) reported Payments to Noncontrolling Interests of $94.80 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-10-20.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToMinorityShareholders · last filed 2021-10-20
- BIOGEN INC. payments to noncontrolling interests for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. payments to noncontrolling interests for the quarter ending 2020-12-31 was -$66.30M, a 1641.86% decline year-over-year.
- BIOGEN INC. payments to noncontrolling interests for the quarter ending 2020-09-30 was $70.90M.
- BIOGEN INC. payments to noncontrolling interests for the quarter ending 2019-12-31 was $4.30M.
- BIOGEN INC. payments to noncontrolling interests for fiscal 2020 was $4.60M.
- BIOGEN INC. payments to noncontrolling interests for fiscal 2019 was $0.00.
- BIOGEN INC. payments to noncontrolling interests for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- BIOGEN INC. payments to noncontrolling interests for fiscal 2017 was $134.10M.
| Period end | Payments to Noncontrolling Interests 3 month | Payments to Noncontrolling Interests 6 month | Payments to Noncontrolling Interests 9 month | Payments to Noncontrolling Interests 12 month | Payments to Noncontrolling Interests 12 month as first filed |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $94.80M 10-Q · filed 2021-10-20 | |||
| 2021-06-30 | $94.80M 10-Q · filed 2021-07-22 | ||||
| 2020-12-31 | -$66.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $4.60M derived: sum of 2 quarters · filed 2021-10-20 | $4.60M 10-K · filed 2021-02-03 | ||
| 2020-09-30 | $70.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $70.90M 10-Q · filed 2021-10-20 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-22 | ||||
| 2019-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $4.30M derived: sum of 2 quarters · filed 2021-02-03 | $0.00 10-K · filed 2021-02-03 | -$4.30M 10-K · filed 2020-02-06 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | -$4.30M 10-Q · filed 2020-10-21 | |||
| 2019-06-30 | -$4.30M 10-Q · filed 2020-07-22 | ||||
| 2018-12-31 | -$36.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | -$38.90M derived: sum of 2 quarters · filed 2021-02-03 | $0.00 10-K · filed 2021-02-03 | $36.40M 10-K · filed 2019-02-06 | |
| 2018-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $36.90M 10-Q · filed 2019-10-22 | |||
| 2018-06-30 | $38.90M 10-Q · filed 2019-07-24 | ||||
| 2017-12-31 | $134.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $134.10M derived: sum of 2 quarters · filed 2020-02-06 | $134.10M 10-K · filed 2020-02-06 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $0.00 10-Q · filed 2018-10-23 | |||
| 2017-06-30 | $0.00 10-Q · filed 2018-07-24 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-06 | ||||
| 2015-12-31 | $56.10M 10-K · filed 2018-02-01 | ||||
| 2012-12-31 | $2.73M 10-K · filed 2013-02-05 | ||||
| 2011-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $17.13M derived: sum of 2 quarters · filed 2013-02-05 | $27.06M 10-K · filed 2013-02-05 | ||
| 2011-09-30 | $14.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $24.11M 10-Q · filed 2011-10-28 | |||
| 2011-06-30 | $9.93M 10-Q · filed 2011-07-26 | ||||
| 2010-12-31 | $17.07M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $25.66M derived: sum of 2 quarters · filed 2013-02-05 | $24.23M derived: sum of 3 quarters · filed 2013-02-05 | $23.48M 10-K · filed 2013-02-05 | |
| 2010-09-30 | $8.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $7.16M derived: sum of 2 quarters · filed 2011-10-28 | $6.40M 10-Q · filed 2011-10-28 | -$787.00K derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | -$2.19M 10-Q · filed 2011-07-26 | -$9.38M derived: sum of 3 quarters · filed 2012-02-03 | ||
| 2010-03-31 | -$760.00K 10-Q · filed 2011-04-21 | -$7.95M derived: sum of 2 quarters · filed 2012-02-03 | |||
| 2009-12-31 | -$7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | -$4.36M 10-K · filed 2012-02-03 | |||
| 2009-09-30 | $2.83M 10-Q · filed 2010-10-26 | ||||
| 2008-12-31 | -$2.05M 10-K · filed 2011-02-04 | ||||
| 2007-12-31 | -$1.88M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |